Thermo Fisher Scientific (TMO) EBT Margin (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported EBT Margin for 18 consecutive years, with 15.76% the latest figure, recorded in Q1 2026.

• EBT Margin for Q1 2026 came in at 15.76%, up 13.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.42% (down 5.0% YoY), and the FY2025 annual result was 16.4%, down 1.0% from the prior year.
• EBT Margin was 15.76% for Q1 2026 at Thermo Fisher Scientific, down from 17.63% in the prior quarter.
• Over five years, EBT Margin peaked at 21.49% in Q2 2022 and troughed at 12.73% in Q2 2023.
• Average EBT Margin over 5 years is 16.18%, with a median of 15.98% recorded in 2023.
• Year-over-year, EBT Margin plunged 877 bps in 2023 and surged 336 bps in 2024.
• Over 5 years, EBT Margin stood at 15.52% in 2022, then advanced by 3 bps to 15.98% in 2023, then grew by 7 bps to 17.03% in 2024, then climbed by 3 bps to 17.63% in 2025, then declined by 11 bps to 15.76% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 15.76% in Q1 2026, 17.63% in Q4 2025, and 16.42% in Q3 2025.